威斯康星医学院眼科专业Michael S. Ip博士报道其研究结果，依据RIDE与RISE随机试验，雷珠单抗可有效控制糖尿病视网膜病变的进展，长达36个月的持续性治疗其疗效更为显著。“我们的数据提示，雷珠单抗用药越晚，效果越差。”

　　PA054

　　Effects of Intravitreal Ranibizumab on Diabetic Retinopathy Severity: 36-Month Data from RISE and RIDE Trials

　　Purpose: To evaluate the effect of intravitreal ranibizumab (RBZ) on diabetic retinopathy (DR) severity through 36 months.

　　Methods: Exploratory analysis of ≥ 2-step and ≥ 3-step change on the Early Treatment Diabetic Retinopathy Study severity scale in the study eye (n = 707) in RISE and RIDE, two Phase 3 clinical trials of monthly RBZ (0.3 or 0.5 mg) vs. sham for diabetic macular edema (DME). In the third year, patients in the sham group were eligible to cross over to 0.5-mg RBZ.

　　Results: At Month 36, compared to sham/crossover, greater proportions of RBZ-treated eyes had ≥2 or ≥3 step regression (improvement) and fewer RBZ-treated eyes had ≥2 or ≥3-step worsening of DR from baseline.

　　Conclusion: Intravitreal RBZ reduced the rate of DR worsening and increased rates of DR improvement in eyes with DME through 36 months.